NEW YORK, NY--(Marketwire - November 30, 2010) - Daxor Corporation (NYSE Amex: DXR), a medical instrumentation and biotechnology company, today announced that the Board of Directors has voted to declare a dividend of $0.65 per share. The dividend will be paid to shareholders of record as of Thursday, December 16, 2010. The dividend will be paid on Thursday, December 30, 2010. 

This is the third dividend the Company has declared for 2010. The Company paid dividends of $0.10 per share on June 16, 2010 and $0.25 per share on September 30, 2010. The total dividends paid in 2010 will be $1.00 per share.

For the year ended December 31, 2009, the Company paid a total dividend of $1.35 per share as follows: $0.10 per share on June 15^th, $0.25 per share on September 8^th and $1.00 per share on December 24, 2009.

These payments are in keeping with the declaration of Company management in 2008 to pay dividends when funds are available.

The Company has chosen to pay each total yearly dividend in three installments in order to allow management greater flexibility in managing the Company's resources. It is management's intention to continue this practice of paying dividends in three installments as long as funds are available to pay dividends. 

The Company plans on filing a new patent application in the near future for the measurement of total body albumin. This measurement will use an advanced version of Daxor's Blood Volume Analyzer (BVA-100). The Company will provide more details on the patent application as the process moves forward.

Daxor Corporation manufactures and markets the BVA-100, the only FDA-approved semi-automated Blood Volume Analyzer. The BVA-100 is used in conjunction with Volumex, Daxor's single use diagnostic kit. For more information regarding Daxor Corporation's Blood Volume Analyzer BVA-100, visit Daxor's website www.Daxor.com.

Contact Information:

Contact Information:

Stephen Feldschuh
Chief Operating Officer
212-330-8515
stephen@daxor.com

David Frankel
Chief Financial Officer
212-330-8504
dfrankel@daxor.com

Dr. Sandra Gilbert, PHD
Clinical Research Coordinator
212-330-8532
sgilbert@daxor.com